29 January 2024
Latham & Watkins Advises on Financing to Support Kindeva Drug Delivery’s Acquisition of Summit Biosciences
Advising firms
Deal team
7 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Stelios Saffos Lead | Latham & Watkins LLP | Partner | Not stated | New York |
| Nicole Fanjul Lead | Latham & Watkins LLP | Partner | Not stated | New York |
| Shahid Jamil | Latham & Watkins LLP | Counsel | Not stated | Chicago |
| Sharon Yin | Latham & Watkins LLP | Associate | Not stated | Not stated |
| Bora Bozkurt | Latham & Watkins LLP | Partner | tax | New York |
| Farrah Yan | Latham & Watkins LLP | Associate | tax | Not stated |
| Michael Yu | Latham & Watkins LLP | Associate | tax | Not stated |
4 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- Not stated
- What the figure measures
- Not stated
- Client
- Latham & Watkins LLPLenders
- Counterparties
- Kindeva Drug Delivery (Buy-side)
Summit Biosciences Inc. (Target)